Sector News

Arbor Pharmaceuticals explores $1 bln-plus sale – sources

October 3, 2014
Life sciences
(Reuters) – Arbor Pharmaceuticals LLC is exploring a sale that could fetch more than $1 billion for the privately-held specialty drugmaker, according to people familiar with the matter.
 
Atlanta, Georgia-based Arbor, which makes prescription drugs for cardiovascular, hospital and pediatric markets, is working with JPMorgan Chase on the potential sale, the people with knowledge of the situation said on Thursday, asking not to be named because the discussions are private.
 
Arbor joins a number of healthcare companies considering a sale at a time when robust buyout appetite from pharmaceutical and biotech companies is driving deal volumes to their highest levels in several years.
 
Representatives for Arbor could not be immediately reached for comment, while JPMorgan declined to comment.
 
The company has branded and generic prescription products for specialty focused conditions in various stages of development, and has 280 sales professionals, according to its website.
 
Its products include Nitrolingual Pumpspray, indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease; EDARBI for the treatment of high blood pressure in adults; and Zenzedi for the treatment of narcolepsy or attention deficit hyperactivity disorder in pediatric patients. (Reporting by Jessica Toonkel and Soyoung Kim in New York; Editing by Tom Brown)

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach